Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.


Press Releases

15 January 2021

Statement on European Upscaling as well as Impact on Deliveries

11 January 2021

Statement on Voluntary COVID-19 Vaccination for BioNTech Employees and Supplier..

8 January 2021

Statement regarding European Commission’s Proposal to Purchase Additional Doses..

Press releases (more)

Upcoming Events

More events are coming soon.

Upcoming events (more)

Stock Quote

Jan 20, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.